In RA, new use of JAK inhibitors was associated with nonmelanoma skin cancer vs. TNF inhibitors at 2 y
- PMID: 37399557
- DOI: 10.7326/J23-0042
In RA, new use of JAK inhibitors was associated with nonmelanoma skin cancer vs. TNF inhibitors at 2 y
Erratum in
-
Corrections to ACP Journal Club: Errors in Clinical Impact Ratings.Ann Intern Med. 2023 Dec;176(12):JC144. doi: 10.7326/J23-0087. Epub 2023 Oct 3. Ann Intern Med. 2023. PMID: 37782926 No abstract available.
Abstract
Huss V, Bower H, Hellgren K, et al; ARTIS group. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study. Ann Rheum Dis. 2023;82:911-919. 36868796.
Conflict of interest statement
Comment on
-
Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.Ann Rheum Dis. 2023 Jul;82(7):911-919. doi: 10.1136/ard-2022-223636. Epub 2023 Mar 3. Ann Rheum Dis. 2023. PMID: 36868796 Free PMC article.